Oncological Pharmacology

Oncological Pharmacology — Expert Level Guide

How it begins

Comprehensive analysis of the mechanisms of action, classification, pharmacokinetics, toxicology, resistance and clinical correlations of antineoplastic agents used in modern medicine.

What it covers

1. Oncological Pharmacology
2. 1. Introduction to Oncological Pharmacology
3. · 1.1 Fundamental Therapeutic Principles
4. · 1.2 Molecular Basis of Cancer Relevant to Pharmacology
5. 2. Cell Cycle and Pharmacological Targets
6. · 2.1 Cellular Cycle Regulatory Machinery
7. · 2.2 Classification by Phase Specificity
8. 3. Pharmacokinetics in Oncology
9. · 3.1 Absorption
10. · 3.2 Distribution
11. · 3.3 Metabolism
12. · 3.4 Elimination
13. · 3.5 Population Pharmacokinetics and PK/PD Modeling
14. 4. Leasing Agents
15. · 4.1 Nitrogenated Mustards
16. · 4.2 Nitrosoureas
17. · 4.3 Platinums (Platinum Analogues)
18. · 4.4 Other Alkylating Agents
19. 5. Antimetabolites
20. · 5.1 Folate Antagonists
21. · 5.2 Pyrimidine Analogues
22. · 5.3 Purine Analogues
23. 6. Antitumor Antibiotics
24. · 6.1 Anthracyclines
25. · 6.2 Bleomycin
26. · 6.3 Mitomycin C
27. · 6.4 Actinomycin D (Dactinomycin)
28. 7. Vegetable Alkaloids and Derivatives
29. · 7.1 Vinca Alkaloids (Vinca rosea)
30. · 7.2 Taxanes (Yew Bark, Taxus brevifolia)
31. · 7.3 Topoisomerase Inhibitors
32. 8. Hormonal and Anti-Hormonal Agents
33. · 8.1 Selective Estrogen Receptor Modulators (SERMs)
34. · 8.2 Aromatase Inhibitors (AIs)
35. · 8.3 Fulvestrant
36. · 8.4 Androgen Deprivation (ADT) in Prostate Cancer
37. 9. Kinase Inhibitors (TKIs)
38. · 9.1 BCR-ABL inhibitors
39. · 9.2 EGFR inhibitors
40. · 9.3 ALK inhibitors
41. · 9.4 BRAF/MEK inhibitors
42. · 9.5 CDK4/6 inhibitors
43. · 9.6 VEGFR (Multitarget Tyrosine Kinase) Inhibitors
44. · 9.7 Other TKIs of Clinical Relevance
45. 10. Monoclonal Antibodies (mAbs)
46. · 10.1 Nomenclature and Types
47. · 10.2 Anti-HER2
48. · 10.3 Anti-VEGF
49. · 10.4 Anti-EGFR (CRC)
50. · 10.5 Antibodies Conjugated to Drugs (ADCs)
51. 11. Oncological immunotherapy
52. · 11.1 Immune Checkpoint Inhibitors (ICIs)
53. · 11.2 Adoptive Cellular Therapy
54. · 11.3 Bispecific Antibodies
55. 12. Other Molecular Targets
56. · 12.1 PI3K/AKT/mTOR inhibitors
57. · 12.2 PARP inhibitors
58. · 12.3 Proteasome Inhibitors
59. · 12.4 Immunomodulatory Drugs (IMiDs)
60. · 12.5 IDH inhibitors
61. · 12.6 Hedgehog Pathway Inhibitors
62. · 12.7 BTK Inhibitors
63. · 12.8 BCL-2 inhibitors
64. 13. Drug Resistance in Oncology
65. · 13.1 Mechanisms of Resistance to Cytotoxics
66. · 13.2 Mechanisms of Resistance to TKIs
67. · 13.3 Resistance to ICIs
68. · 13.4 Strategies to Overcome Resistance
69. 14. Toxicity and Management of Adverse Effects
70. · 14.1 Myelosuppression
71. · 14.2 Nausea and Vomiting induced by Chemotherapy (CINV)
72. · 14.3 Mucositis
73. · 14.4 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
74. · 14.5 Tumor Lysis Syndrome (TLS)
75. · 14.6 Vesicant Extravasation Syndrome
76. 15. Drug Interactions in Oncology
77. · 15.1 Critically Important Drug Interactions
78. · 15.2 Interactions with Anticoagulants
79. · 15.3 Pharmacodynamic Interactions
80. 16. Special Populations
81. · 16.1 Kidney Failure
82. · 16.2 Liver Failure
83. · 16.3 Geriatric Oncology
84. · 16.4 Pregnancy and Cancer
85. 17. Principles of Combination Therapy
86. · 17.1 Emblematic Combination Protocols
87. · 17.2 Concept of Dose Intensity
88. · 17.3 Pharmacological Synergy
89. 18. Emerging Therapies and Future Perspectives
90. · 18.1 PROTACs and Protein Degraders
91. · 18.2 Therapeutic Vaccines against Cancer
92. · 18.3 Radiopharmaceutical Therapies
93. · 18.4 Epigenetic Degraders and Modulators
94. · 18.5 Therapies Directed at DNA and Repair
95. · 18.6 Precision Oncology and Tumor Agnostic Approvals
96. · 18.7 Signaling Antagonists in the Tumor Microenvironment
97. · 18.8 Artificial Intelligence in Oncological Pharmacology